Compare HSBC Holdings plc (HSBC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Tango Therapeutics Inc. — how do they compare? HSBC Holdings plc trades at $94.48 (market cap $323.18B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: HSBC Holdings plc is far larger — about 86.2× Tango Therapeutics Inc.'s market cap, and HSBC Holdings plc pays a 3.95% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 37 Days and Tango Therapeutics Inc. for 0 Days on average.
| HSBC | TNGX | |
|---|---|---|
Market Cap | $323.18B | $3.75B |
Volume | 1,876,560 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $107.86 | $32.90 |
52-Week Low | $65.67 | $7.50 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $229.73B | $2.77B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $94.85, up 0.56% today, with a bearish technical signal from moving averages and ADX. The stock shows solid fundamentals with a P/E of 13.55, net income margin of 34.54%, and recent earnings beats in Q4 2025 and Q2 2026. Recent news highlights strategic expansions in TMT banking and India equity broking, alongside a planned CFO transition in 2027.
The outlook is mixed: valuation appears reasonable and profitability is strong, but technical indicators signal caution and analyst consensus leans Hold. Key risks include execution of growth initiatives and macroeconomic pressures. The stock offers income with a $0.50 dividend, but investors should weigh near-term technical weakness against long-term fundamental strength.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
